[go: up one dir, main page]

WO2004056338A3 - Gels stables non aqueux a phase unique et formulations, destines a etre administres a partir d'un dispositif implantable - Google Patents

Gels stables non aqueux a phase unique et formulations, destines a etre administres a partir d'un dispositif implantable Download PDF

Info

Publication number
WO2004056338A3
WO2004056338A3 PCT/US2003/040929 US0340929W WO2004056338A3 WO 2004056338 A3 WO2004056338 A3 WO 2004056338A3 US 0340929 W US0340929 W US 0340929W WO 2004056338 A3 WO2004056338 A3 WO 2004056338A3
Authority
WO
WIPO (PCT)
Prior art keywords
delivery
present
beneficial agent
formulations
stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/040929
Other languages
English (en)
Other versions
WO2004056338A9 (fr
WO2004056338A2 (fr
Inventor
Stephen Berry
Pamela J Fereira
Gunjan Junnarkar
Michael A Desjardin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2003297464A priority Critical patent/AU2003297464A1/en
Priority to JP2004562364A priority patent/JP2006512370A/ja
Priority to BR0317421-2A priority patent/BR0317421A/pt
Priority to EP03813829A priority patent/EP1578398A2/fr
Priority to CA002508124A priority patent/CA2508124A1/fr
Priority to MXPA05006604A priority patent/MXPA05006604A/es
Application filed by Alza Corp filed Critical Alza Corp
Publication of WO2004056338A2 publication Critical patent/WO2004056338A2/fr
Publication of WO2004056338A9 publication Critical patent/WO2004056338A9/fr
Publication of WO2004056338A3 publication Critical patent/WO2004056338A3/fr
Anticipated expiration legal-status Critical
Priority to NO20053439A priority patent/NO20053439L/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
    • A61L24/001—Use of materials characterised by their function or physical properties
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Materials Engineering (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un support de suspension et des formulations en suspension pouvant être administrées à partir d'un dispositif d'administration implantable. Le support de suspension de la présente invention permet, en particulier, de formuler des suspensions d'agents bénéfiques stables dans la durée à température ambiante et physiologique. De plus, les suspensions d'agents bénéfiques formées à l'aide du support de suspension de la présente invention permettent de procéder à une administration contrôlée de l'agent bénéfique à partir d'un dispositif d'administration implanté sur des périodes de temps prolongées, y compris lorsqu'une telle administation se produit à faible débit, à travers un canal d'administration de diamètre réduit. La présente invention concerne également des dispositifs d'administration.
PCT/US2003/040929 2002-12-19 2003-12-19 Gels stables non aqueux a phase unique et formulations, destines a etre administres a partir d'un dispositif implantable Ceased WO2004056338A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2004562364A JP2006512370A (ja) 2002-12-19 2003-12-19 安定な非水性単相ゲル、および植込み型デバイスから送達するためのその配合物
BR0317421-2A BR0317421A (pt) 2002-12-19 2003-12-19 Géis de fase única não-aquosa estável e formulações destes para liberação a partir de um dispositivo implantável
EP03813829A EP1578398A2 (fr) 2002-12-19 2003-12-19 Gels stables non aqueux a phase unique et formulations, destines a etre administres a partir d'un dispositif implantable
CA002508124A CA2508124A1 (fr) 2002-12-19 2003-12-19 Gels stables non aqueux a phase unique et formulations, destines a etre administres a partir d'un dispositif implantable
MXPA05006604A MXPA05006604A (es) 2002-12-19 2003-12-19 Geles de una sola fase, no acuosos, estables, y formulaciones de los mismos para el suministro desde un aparato implantable.
AU2003297464A AU2003297464A1 (en) 2002-12-19 2003-12-19 Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device
NO20053439A NO20053439L (no) 2002-12-19 2005-07-15 Stabile, ikke-vandige, enkeltfasegeler og formuleringer derav for avlevering fra en implementerbar innretning

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43518002P 2002-12-19 2002-12-19
US60/435,180 2002-12-19

Publications (3)

Publication Number Publication Date
WO2004056338A2 WO2004056338A2 (fr) 2004-07-08
WO2004056338A9 WO2004056338A9 (fr) 2004-12-02
WO2004056338A3 true WO2004056338A3 (fr) 2005-02-17

Family

ID=32682177

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/040929 Ceased WO2004056338A2 (fr) 2002-12-19 2003-12-19 Gels stables non aqueux a phase unique et formulations, destines a etre administres a partir d'un dispositif implantable

Country Status (13)

Country Link
US (2) US20040224903A1 (fr)
EP (1) EP1578398A2 (fr)
JP (1) JP2006512370A (fr)
KR (1) KR20050088196A (fr)
CN (1) CN1726008A (fr)
AU (1) AU2003297464A1 (fr)
BR (1) BR0317421A (fr)
CA (1) CA2508124A1 (fr)
MX (1) MXPA05006604A (fr)
NO (1) NO20053439L (fr)
RU (1) RU2342118C2 (fr)
WO (1) WO2004056338A2 (fr)
ZA (1) ZA200505743B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
MXPA04012976A (es) * 2002-06-17 2005-05-16 Alza Corp Sistema de distribucion osmotica con medio de potencia de empuje de orden cero temprana que comprende un agente osmotico disperso en el vehiculo fluido.
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
AU2003270427A1 (en) * 2002-09-06 2004-03-29 University Of South Florida Cellular delivery of natriuretic peptides
US7655772B2 (en) 2002-09-06 2010-02-02 University Of South Florida Materials and methods for treatment of allergic diseases
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US8071560B2 (en) * 2004-02-17 2011-12-06 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
AU2003299659A1 (en) 2002-12-13 2004-07-09 Durect Corporation Oral drug delivery system comprising high viscosity liquid carrier materials
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
WO2004089335A2 (fr) * 2003-03-31 2004-10-21 Alza Corporation Excipients monophasiques non aqueux et formulations les contenant
US20050010196A1 (en) * 2003-03-31 2005-01-13 Fereira Pamela J. Osmotic delivery system and method for decreasing start-up times for osmotic delivery systems
CN100548411C (zh) * 2003-03-31 2009-10-14 精达制药公司 设置有内部压力释放部件的渗透泵
MXPA06002030A (es) * 2003-10-31 2006-05-17 Alza Corp Bomba osmotica con tapon de membrana de auto-retencion, de rapido inicio.
WO2005046639A2 (fr) * 2003-11-06 2005-05-26 Alza Corporation Dispositif de reduction du taux d'imbition modulaire utilise avec une pompe osmotique implantable
CA2559853A1 (fr) * 2004-02-17 2005-10-13 University Of South Florida Materiaux et methodes permettant de traiter des troubles inflammatoires et lies a la proliferation cellulaire
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US7772182B2 (en) * 2004-08-05 2010-08-10 Alza Corporation Stable suspension formulations of erythropoietin receptor agonists
WO2006033948A2 (fr) 2004-09-17 2006-03-30 Durect Corporation Systeme de distribution commandee
WO2006083761A2 (fr) * 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
WO2006084139A2 (fr) 2005-02-03 2006-08-10 Intarcia Therapeutics, Inc. Dispositif implantable pour administration en continu d'interferon
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US7959938B2 (en) * 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
EP2359808B1 (fr) 2006-08-09 2013-05-22 Intarcia Therapeutics, Inc Système de libération osmotique avec ensemble de piston
AU2007325918B2 (en) 2006-11-03 2013-10-17 Durect Corporation Transdermal delivery systems comprising bupivacaine
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
CA2706931C (fr) 2007-12-06 2015-05-12 Durect Corporation Formes posologiques pharmaceutiques orales
WO2009102467A2 (fr) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Dispositifs, formulations et méthodes d’administration de plusieurs agents bénéfiques
CA2738715C (fr) * 2008-10-15 2013-07-16 Intarcia Therapeutics, Inc. Particules medicamenteuses hautement concentrees, formes pharmaceutiques, suspensions et leurs utilisations
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
RU2753280C2 (ru) * 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
CN103814132B (zh) * 2011-09-20 2018-06-05 苏州瑞博生物技术有限公司 Gcgr表达的反义调节
CN105120659A (zh) 2013-03-15 2015-12-02 度瑞公司 用于降低溶解可变性的具有流变改性剂的组合物
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
WO2016196851A2 (fr) 2015-06-03 2016-12-08 Intarcia Therapeutics, Inc. Systèmes de mise en place et de retrait d'implant
CN105470566B (zh) * 2015-11-18 2018-06-26 何整风 一种全固态电池及其制备方法
JP7077237B2 (ja) 2016-05-16 2022-05-30 インターシア セラピューティクス，インコーポレイティド グルカゴン受容体選択的ポリペプチド及びその使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
AU2017292791B2 (en) 2016-07-06 2023-05-25 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
US20220257619A1 (en) 2019-07-18 2022-08-18 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
WO2021146215A1 (fr) 2020-01-13 2021-07-22 Durect Corporation Systèmes d'administration de médicament à libération prolongée avec impuretés réduites et procédés associés
KR20230145053A (ko) 2021-01-12 2023-10-17 듀렉트 코퍼레이션 지속 방출 약물 전달 시스템 및 관련 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
WO2001078683A2 (fr) * 2000-04-19 2001-10-25 Genentech, Inc. Formulations a liberation lente
WO2002028366A2 (fr) * 2000-10-06 2002-04-11 Durect Corporation Systèmes et méthodes permettant d'agir sur une inflammation
WO2002067895A2 (fr) * 2000-11-16 2002-09-06 Durect Corporation Dispositifs et procedes servant a lutter contre le cholesterol
WO2002076344A1 (fr) * 2001-03-23 2002-10-03 Durect Corporation Administration de medicaments au moyen de dispositifs a liberation lente implantes dans un tissu myocardique ou dans la cavite pericardique

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
DE4137649C2 (de) * 1991-11-15 1997-11-20 Gerhard Dingler Bauelement
US5368588A (en) * 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
US5697975A (en) * 1994-02-09 1997-12-16 The University Of Iowa Research Foundation Human cerebral cortex neural prosthetic for tinnitus
EP0788351B1 (fr) * 1994-11-10 2003-02-05 The University of Kentucky Research Foundation Dispositif implantable et rechargeable a diffusion controlee pour l'administration de medicaments directement dans une partie interne du corps
US6413536B1 (en) * 1995-06-07 2002-07-02 Southern Biosystems, Inc. High viscosity liquid controlled delivery system and medical or surgical device
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
JP4330175B2 (ja) * 1995-06-07 2009-09-16 デュレクト コーポレイション 高粘度液体による制御された送達系
US5782396A (en) * 1995-08-28 1998-07-21 United States Surgical Corporation Surgical stapler
US6156331A (en) * 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
ATE235224T1 (de) * 1996-02-02 2003-04-15 Alza Corp Implantierbares system mit verzögerter freisetzung von leuprolid
US6132420A (en) * 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6395292B2 (en) * 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US5976109A (en) * 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US5985306A (en) * 1996-10-28 1999-11-16 Novo Nordisk A/S (+)-enantiomers of cis-3,4-chroman derivatives useful in prevention or treatment of estrogen diseases or syndromes
CA2275525C (fr) * 1996-12-20 2011-02-08 Kevin J. Brodbeck Compositions a base de gel et procedes connexes
ZA981610B (en) * 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
DK1041975T3 (da) * 1997-12-22 2002-11-04 Alza Corp Hastighedskontrollerende membraner til anordninger til kontrolleret indførsel af medikament
CA2316976C (fr) * 1997-12-29 2009-02-17 Alza Corporation Dispositif d'administration osmotique avec mecanisme de retention pour bouchon a membrane
KR100568917B1 (ko) * 1997-12-30 2006-04-07 알자 코포레이션 멤브레인 플러그를 갖는 익제 전달장치
US6248112B1 (en) * 1998-09-30 2001-06-19 C. R. Bard, Inc. Implant delivery system
ATE234603T1 (de) * 1998-12-31 2003-04-15 Alza Corp Osmotisches verabreichungsystem mit raumsparenden kolben
WO2000045790A2 (fr) * 1999-02-08 2000-08-10 Alza Corporation Excipients visqueux a phase unique non aqueux stables et formulations utilisant ces excipients
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6436091B1 (en) * 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
DE60023361T2 (de) * 1999-12-21 2006-04-27 Alza Corp., Mountain View Ventil für osmotische vorrichtungen
US6283949B1 (en) * 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
US7163688B2 (en) * 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
US20030138403A1 (en) * 2001-06-29 2003-07-24 Maxygen Aps Interferon formulations
MXPA04012976A (es) * 2002-06-17 2005-05-16 Alza Corp Sistema de distribucion osmotica con medio de potencia de empuje de orden cero temprana que comprende un agente osmotico disperso en el vehiculo fluido.
ATE376854T1 (de) * 2002-06-26 2007-11-15 Alza Corp Minimal nachgiebiger volumen-effizienter kolben für osmotische medikamentenabgabesysteme
US7014636B2 (en) * 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
CN100548411C (zh) * 2003-03-31 2009-10-14 精达制药公司 设置有内部压力释放部件的渗透泵

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747058A (en) * 1995-06-07 1998-05-05 Southern Biosystems, Inc. High viscosity liquid controlled delivery system
WO2001078683A2 (fr) * 2000-04-19 2001-10-25 Genentech, Inc. Formulations a liberation lente
WO2002028366A2 (fr) * 2000-10-06 2002-04-11 Durect Corporation Systèmes et méthodes permettant d'agir sur une inflammation
WO2002067895A2 (fr) * 2000-11-16 2002-09-06 Durect Corporation Dispositifs et procedes servant a lutter contre le cholesterol
WO2002076344A1 (fr) * 2001-03-23 2002-10-03 Durect Corporation Administration de medicaments au moyen de dispositifs a liberation lente implantes dans un tissu myocardique ou dans la cavite pericardique

Also Published As

Publication number Publication date
WO2004056338A9 (fr) 2004-12-02
NO20053439L (no) 2005-07-15
CA2508124A1 (fr) 2004-07-08
BR0317421A (pt) 2005-11-08
JP2006512370A (ja) 2006-04-13
ZA200505743B (en) 2006-10-25
WO2004056338A2 (fr) 2004-07-08
RU2005122654A (ru) 2006-01-20
EP1578398A2 (fr) 2005-09-28
US20090087408A1 (en) 2009-04-02
KR20050088196A (ko) 2005-09-02
AU2003297464A1 (en) 2004-07-14
MXPA05006604A (es) 2006-05-25
US20040224903A1 (en) 2004-11-11
RU2342118C2 (ru) 2008-12-27
CN1726008A (zh) 2006-01-25

Similar Documents

Publication Publication Date Title
WO2004056338A3 (fr) Gels stables non aqueux a phase unique et formulations, destines a etre administres a partir d'un dispositif implantable
WO2004073765A8 (fr) Dispositif d'administration de medicaments et seringue permettant de le remplir
PL1543851T3 (pl) Wszczepialne urządzenie do podawania substancji czynnej
IL169287A (en) Sterile ophthalmic formulation, an ocular insert for delivery of same and the use of the formulation
IL162110A0 (en) Micronized film-forming powder comprising an active substance
WO2003074551A8 (fr) Conjugues d'agents therapeutiques ou cytotoxiques et de peptides bioactifs
DE60135352D1 (de) Vorrichtung zur intraokularen wirkstoffverabreichung
WO2006039467A3 (fr) Dispositifs biomedicaux contenant des copolymeres sequences amphiphiles
MXPA02003130A (es) Formulaciones topicas en suspension que contienen ciprofloxacino y dexametasona.
WO2004064769A3 (fr) Methodes de production et d'utilisation d'agents d'administration topique
AU2002224777A1 (en) Device for controlling, regulating and/or putting an active implant into operation
WO2004091446A3 (fr) Systemes de mise en place de dispositifs medicaux
MXPA03007590A (es) Composiciones y metodos para mejorar suministro de droga a traves de y dentro de tejidos oculares.
WO2002080993A3 (fr) Revetement pour dispositifs medicaux
IL164152A0 (en) Drug microparticles
AUPS081502A0 (en) Connector for drug delivery system
WO2007019554A3 (fr) Polysaccharides destines a l'administration de principes actifs
AU6471500A (en) Aqueous nasal formulation
EP1411876A4 (fr) Systeme pour dispositifs implantes
TW200509998A (en) Controlled release of highly soluble agents
TW200501964A (en) Lipid-regulating agent and its usage
TW200517115A (en) Modulation of interleukin-10 by DHEA
WO2006076708A3 (fr) Procede et appareil pour la pose a invasion minimale d'ensembles de detection et d'amplification pour l'amelioration de perte auditive
WO2003053365A3 (fr) Compositions de syn3 et procedes associes
MXPA05007584A (es) Composiciones de termiticida.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
COP Corrected version of pamphlet

Free format text: PAGE 5, DESCRIPTION, REPLACED BY A NEW PAGE 5

WWE Wipo information: entry into national phase

Ref document number: 540274

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003297464

Country of ref document: AU

Ref document number: 993/KOLNP/2005

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2508124

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 168966

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/006604

Country of ref document: MX

Ref document number: 20038A6441X

Country of ref document: CN

Ref document number: 1020057011459

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2004562364

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2005/05743

Country of ref document: ZA

Ref document number: 200505743

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2005122654

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2003813829

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020057011459

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003813829

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0317421

Country of ref document: BR